ArticleJournal of medical biochemistry2026
Prognostic significance of circulating immune-inflammatory biomarkers IL-6 and systemic immune-inflammation index in hepatocellular carcinoma treated with immune checkpoint inhibitors: A meta-analysis.
Article in Journal of medical biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatocellular carcinoma (HCC) is characterized by a chronic inflammatory and immunologically dysregulated microenvironment. Circulating immune-inflammatory biomarkers reflect systemic biochemical and immune alterations and may provide laboratory-accessible indicators for prognosis assessment. However, the prognostic value of interleukin-6 (IL-6) and the systemic immune-inflammation index (SII) in HCC patients receiving immune checkpoint inhibitors (ICIs) remains incompletely defined. Methods: A comprehensive literature search was conducted across PubMed, Embase, Web of Science, the Cochrane Library, CNKI, and Wanfang Data to identify cohort studies evaluating circulating IL-6 and/or SII in HCC patients treated with ICIs. Hazard ratios (HR) with 95% confidence intervals (CI) for progression-free survival (PFS) and overall survival (OS) were pooled using fixedor random-effects models. Subgroup and sensitivity analyses were performed to explore sources of heterogeneity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.